Organogenesis Acquires Shire’s Dermagraft Amid Reimbursement Challenges
This article was originally published in The Gray Sheet
Executive Summary
Dublin-based Shire’s decision to sell Dermagraft and its assets to its competitor was made in light of substantial Medicare pay cuts that took effect this year based on policies in CMS’ 2014 hospital outpatient prospective payment system regulation.
You may also be interested in...
Shire To Pay Record-Setting Device FCA Settlement
The $350m settlement resolves False Claims Act allegations Shire and its subsidiaries used tactics including lavish meals, free medical equipment, unearned speaker payments and cash to encourage doctors to prescribe the company’s Dermagraft human skin substitute.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.